目的 探討腫節(jié)風(fēng)注射液聯(lián)合阿帕替尼治療晚期胃癌的臨床療效。方法 回顧性分析2012年2月—2016年9月在安陽(yáng)市第五人民醫(yī)院治療的46例晚期胃癌患者的臨床資料，根據(jù)治療方案的差別分成對(duì)照組（23例）和治療組（23例）。對(duì)照組患者于術(shù)后餐后30 min口服甲磺酸阿帕替尼片，850 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注腫節(jié)風(fēng)注射液，4 mL/次，1次/d。兩組患者均治療4周。比較兩組患者治療前后臨床療效、生存質(zhì)量和血清學(xué)指標(biāo)改善情況。結(jié)果 治療后，對(duì)照組客觀緩解率（ORR）和臨床獲益率（CBR）分別為39.13%、47.83%，均顯著低于治療組的65.22%和78.26%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，對(duì)照組和治療組的生存質(zhì)量改善率分別為69.57%和91.30%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者血清血管內(nèi)皮細(xì)胞生長(zhǎng)因子（VEGF）、S100A4、基質(zhì)金屬蛋白酶2（MMP-2）水平均顯著降低，而IL-12和γ-干擾素（IFN-γ）水平顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組上述血清學(xué)指標(biāo)變化水平顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 腫節(jié)風(fēng)注射液聯(lián)合阿帕替尼治療晚期胃癌的臨床效果顯著，可有效改善患者生活質(zhì)量和提高機(jī)體免疫力，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Zhongjiefeng Injection combined with apatinib in treatment of advanced gastric cancer. Methods The clinical data of patients (46 cases) with advanced gastric cancer in the Fifth People's Hospital of Anyang from February 2012 to September 2016 were retrospectively analyzed and divided into control (23 cases) and treatment (23 cases) groups based on different treatments. Patients in the control group were postoperative po administered with Apatinib Mesylate Tablets 30 m after meal, 850 mg/time, once daily. Patients in the treatment group were iv administered with Zhongjiefeng Injection on the basis of the control group, 4 mL/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the improvement of clinical efficacy, quality of life, and serological indexes in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group was 39.13% and 47.83%, which were significantly lower than 65.22% and 78.26% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the quality of life improvement rate in the control and treatment groups were 69.57% and 91.30%, respectively, and there was difference between two groups (P < 0.05). After treatment, the VEGF, S100A4, and MMP-2 levels in two groups significantly decreased, but IL-12 and IFN-γ levels increased, and the difference was statistically significant in the same group (P < 0.05). And the change of these serological indexes in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Zhongjiefeng Injection combined with apatinib has significant clinical effect in treatment of advanced gastric cancer, can effectively improve the life quality and immunity, which has a certain clinical application value.